Evidence map›Paper›PMID 35506079›Full record

ArticlePulmonary circulation2022

Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension.

Catherine E Simpson, Todd M Kolb, Steven Hsu, Stefan L Zimmerman, Celia P Corona-Villalobos, Stephen C Mathai, Rachel L Damico, Paul M Hassoun

Open access · goldAbstract read
In one paragraph

Article in Pulmonary circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Catherine E SimpsonDepartment of Medicine, Division of Pulmonary and Critical Care Medicine Johns Hopkins University Baltimore Maryland USA.ORCID 0000-0002-2388-5660
Todd M KolbDepartment of Medicine, Division of Pulmonary and Critical Care Medicine Johns Hopkins University Baltimore Maryland USA.
Steven HsuDepartment of Medicine, Division of Cardiology Johns Hopkins University Baltimore Maryland USA.
Stefan L ZimmermanDepartment of Radiology and Radiological Science Johns Hopkins University Baltimore Maryland USA.
Celia P Corona-VillalobosDepartment of Medicine, Division of Nephrology Johns Hopkins University Baltimore Maryland USA.
Stephen C MathaiDepartment of Medicine, Division of Pulmonary and Critical Care Medicine Johns Hopkins University Baltimore Maryland USA.
Rachel L DamicoDepartment of Medicine, Division of Pulmonary and Critical Care Medicine Johns Hopkins University Baltimore Maryland USA.
Paul M HassounDepartment of Medicine, Division of Pulmonary and Critical Care Medicine Johns Hopkins University Baltimore Maryland USA.
Johns Hopkins University · US

Funding

SCLERODERMA-ASSOCIATED PAHP50HL084946 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLUEMKE, DAVID A. · 2007 to 2011
$20.6M
Mechanisms of Right Ventricular Dysfunction in Scleroderma-associated PAHR01HL114910 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M. · 2012 to 2023
$6.2M
Hopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1M
Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertensionK23HL146889 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HSU, STEVEN · 2019 to 2023
$886k
The role of xanthine oxidoreductase activity and altered metabolism in scleroderma-associated pulmonary arterial hypertensionK23HL153781 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SIMPSON, CATHERINE · 2020 to 2024
$883k
NHLBI NIH HHS K23 HL146889NHLBI NIH HHS K23 HL153781NHLBI NIH HHS P50 HL084946NHLBI NIH HHS R01 HL114910NHLBI NIH HHS U01 HL125175
6 · The paper itself

Abstract

Cardiac magnetic resonance (CMR) measures of right ventricular (RV) mass, volumes, and function have diagnostic and prognostic value in pulmonary arterial hypertension (PAH). We hypothesized that RV mass-based metrics would discriminate incident PAH as redefined by the lower mean pulmonary arterial pressure (mPAP) threshold of >20 mmHg at the Sixth World Symposium on Pulmonary Hypertension (6th WSPH). Eighty-nine subjects with suspected PAH underwent CMR imaging, including 64 subjects with systemic sclerosis (SSc). CMR metrics, including RV and left ventricular (LV) mass, were measured. All subjects underwent right heart catheterization (RHC) for assessment of hemodynamics within 48 h of CMR. Using generalized linear models, associations between CMR metrics and PAH were assessed, the best subset of CMR variables for predicting PAH were identified, and relationships between mass-based metrics, hemodynamics, and other predictive CMR metrics were examined. Fifty-nine subjects met 6th WSPH criteria for PAH. RV mass metrics, including ventricular mass index (VMI), demonstrated the greatest magnitude difference between subjects with versus without PAH. Overall and in SSc, VMI and RV mass measured by CMR were among the most predictive variables discriminating PAH at RHC, with areas under the receiver operating characteristic curve 0.86 and 0.83. respectively. VMI increased linearly with pulmonary vascular resistance and with mPAP in PAH, including in lower ranges of mPAP associated with mild PAH. VMI ≥ 0.37 yielded a positive predictive value of 90% for discriminating PAH. RV mass metrics measured by CMR, including VMI, discriminate incident, treatment-naïve PAH as defined by 6th WSPH criteria.

Indexed as

diagnosismagnetic resonance imagingpulmonary hypertension

Identifiers

PMID35506079
PMCPMC9052971
OpenAlexW4200433434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.